Regulacje i polityka gospodarcza · 14/09/2006

NIH Considers Exclusive License for Cancer Treatment T-Cell Receptor

The National Institutes of Health is considering granting an exclusive patent license to CellCure A/S to use a specific T-cell receptor for cancer treatment. The license would cover the use of a T-cell receptor recognizing a MART-1 peptide restricted by HLA-A2 in a continuous T-Lymphocyte cell line.